Curevac N.V. (CVAC) has disclosed a new risk, in the Demand category.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Curevac N.V. faces considerable business risk as their market estimates for product candidates may not align with reality. Derived from various sources, their patient population calculations could be flawed, especially if new research alters disease incidence or prevalence understanding. Additionally, securing sufficient clinical trial participants poses a challenge, as individuals may resist their treatment methods. Even with market penetration, the small target demographics could render Curevac’s products unprofitable, irrespective of regulatory approval.
Overall, Wall Street has a Moderate Buy consensus rating on CVAC stock based on 1 Buy and 1 Hold.
To learn more about Curevac N.V.’s risk factors, click here.